Southeast Asian patients with chronic hepatitis C: The impact of novel genotypes and race on treatment outcome
- 1 November 2002
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 36 (5), 1259-1265
- https://doi.org/10.1053/jhep.2002.36781
Abstract
Hepatitis C virus (HCV) genotype and other host and viral factors influence treatment outcome in chronic HCV infection. We evaluated the effect of race and genotype on interferon and ribavirin treatment outcome in 70 Southeast Asian (SEA) and 50 white patients. Genotype was based on the 5' untranslated region (5'UTR) with a commonly used line probe assay (INNO-LiPA HCV II) that may mistype genotype 7, 8, or 9 as 1b. HCV core region sequencing resulted in reclassification of 8 genotype 1 and 25 genotype 1b SEA subjects as genotype 7, 8, or 9. Twenty-six SEA genotype 7, 8, and 9 (79%) and 10 SEA true genotype 1b (59%) patients achieved a sustained virologic response (SVR) compared with 15 (34%) white genotype 1b patients. Logistic regression analysis showed that SEA patients with genotype 7, 8, or 9 were more likely to achieve a SVR than white genotype 1b patients (OR 16.56; 95%CI 4.16, 65.91) as were SEA true genotype 1b patients compared with white genotype 1b patients (OR 4.63; 95%CI 1.19, 18.04). In conclusion, a proportion of SEA patients classified by INNO-LiPA as genotype 1b were in reality genotype 7, 8, or 9. In comparison with white genotype 1b patients, both SEA genotype 1b and SEA genotype 7, 8, and 9 patients showed a significantly greater SVR. HCV core sequencing was necessary to determine genotype accurately in persons potentially exposed to HCV genotypes 7, 8, or 9. This study also supports the concept that race and ethnicity are important determinants of treatment outcome in HCV infected patients.This publication has 36 references indexed in Scilit:
- The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis CGastroenterology, 2000
- Which patients with hepatitis C develop liver complications?Hepatology, 2000
- Racial differences in responses to therapy with interferon in chronic hepatitis CHepatology, 1999
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CThe New England Journal of Medicine, 1998
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusThe Lancet, 1998
- 10-year follow-up after interferon-? therapy for chronic hepatitis CHepatology, 1998
- Hepatitis CThe Lancet, 1998
- Factors predictive of a beneficial response to therapy of hepatitis CHepatology, 1997
- Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis CHepatology, 1995
- Long-Term Mortality after Transfusion-Associated Non-A, Non-B HepatitisThe New England Journal of Medicine, 1992